4.7 Article

RespiFinder: a new multiparameter test to differentially identify fifteen respiratory viruses

期刊

JOURNAL OF CLINICAL MICROBIOLOGY
卷 46, 期 4, 页码 1232-1240

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/JCM.02294-07

关键词

-

向作者/读者索取更多资源

Broad-spectrum analysis for pathogens in patients with respiratory tract infections is becoming more relevant as the number of potential infectious agents is still increasing. Here we describe the new multiparameter RespiFinder assay, which is based on the multiplex ligation-dependent probe amplification (MLPA) technology. This assay detects 15 respiratory viruses in one reaction. The MLPA reaction is preceded by a preamplification step which ensures the detection of both RNA and DNA viruses with the same specificity and sensitivity as individual monoplex real-time reverse transcription-PCRs. The RespiFinder assay was validated with 144 clinical samples, and the results of the assay were compared to those of cell culture and a respiratory syncytial virus (RSV)-specific immunochromatography assay (ICA). Compared to the cell culture results, the RespiFinder assay showed specificities and sensitivities of 98.2% and 100%, respectively, for adenovirus; 96.4% and 100%, respectively, for human metapneumovirus; 98.2% and 100%, respectively, for influenza A virus (InfA); 99.1% and 100%, respectively, for parainfluenza virus type I (PIV-1); 99.1% and 80%, respectively, for PIV-3; 90.1% and 100%, respectively, for rhinovirus; and 94.6%-and 100%, respectively, for RSV. Compared to the results of the RSV-specific ICA, the RespiFinder assay gave a specificity and a sensitivity of 82.4% and 80%, respectively. PIV-2, PIV-4, influenza B virus, InfA H5N1, and coronavirus 229E were not detected in the clinical specimens tested. The use of the RespiFinder assay resulted in an increase in the diagnostic yield compared to that obtained by cell culture (diagnostic yields, 60% and 35.5%, respectively). In conclusion, the RespiFinder assay provides a user-friendly and high-throughput tool for the simultaneous detection of 15 respiratory viruses with excellent overall performance statistics.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Orthopedics

Cutibacterium acnes infections in revision surgery for persistent shoulder complaints: a retrospective cohort study

Nathalie Pruijn, Floor M. van Diek, Jacques F. Meis, Nienke M. Kosse, Oscar Dorrestijn

Summary: The study found that the incidence of C. acnes infections was around 42% in patients with and without artificial material after shoulder surgery. Risk factors identified were age and BMI. Low-grade C. acnes infections should be considered in patients with unexplained persistent complaints following shoulder surgery.

ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY (2021)

Article Infectious Diseases

Ruling out underlying infection in 200 presumed aseptic knee and hip revision arthroplasties using a multiplex PCR system

Anouk M. E. Jacobs, Petra J. C. Heesterbeek, Frans A. T. Bovendeert, Saskia Susan, Jacques F. Meis, Jon H. M. Goosen

Summary: The study evaluated the diagnostic accuracy of an automated mPCR of synovial fluid in unsuspected knee and hip revisions. In knee revisions, mPCR showed high specificity and NPV, while in hip revisions, it had lower sensitivity but higher specificity and NPV.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2021)

Article Infectious Diseases

In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species

Ashutosh Singh, Prerna Singh, Jacques F. Meis, Anuradha Chowdhary

Summary: Olorofim demonstrates potent in vitro activity against drug-resistant dermatophytes and opportunistic moulds, with exceptions in Alternaria alternata. When compared to other systemic antifungal drugs, Olorofim exhibits lower activity against Penicillium and Talaromyces species. Particularly, Olorofim shows strong activity against Trichophyton isolates, including those resistant to terbinafine and azoles.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

Article Dermatology

Activities of nine antifungal agents against Candida auris biofilms

Athanasios Chatzimoschou, Athina Giampani, Jacques F. Meis, Emmanuel Roilides

Summary: Candida auris exhibits higher MICs for fluconazole and relatively low MICs for itraconazole, posaconazole, and voriconazole. Echinocandins and liposomal amphotericin B also show lower activity against C auris biofilms compared to deoxycholate amphotericin B.

MYCOSES (2021)

Article Dermatology

A pseudo-outbreak of Rhinocladiella similis in a bronchoscopy unit of a tertiary care teaching hospital in London, United Kingdom

Alireza Abdolrasouli, Malick M. Gibani, Theun de Groot, Andrew M. Borman, Peter Hoffman, Berge S. Azadian, Nabeela Mughal, Luke S. P. Moore, Elizabeth M. Johnson, Jacques F. Meis

Summary: This study investigated a pseudo-outbreak of Rhinocladiella similis in a bronchoscopy unit of a tertiary care teaching hospital in London. The potential source of contamination was determined to be a bronchoscope, but no infections were found in patients after the outbreak. The study emphasizes the importance of prolonged fungal culture and species-level identification in bronchoscopy samples.

MYCOSES (2021)

Article Microbiology

Colonisation and Transmission Dynamics of Candida auris among Chronic Respiratory Diseases Patients Hospitalised in a Chest Hospital, Delhi, India: A Comparative Analysis of Whole Genome Sequencing and Microsatellite Typing

Anamika Yadav, Anubhav Singh, Yue Wang, Merlijn H. van Haren, Ashutosh Singh, Theun de Groot, Jacques F. Meis, Jianping Xu, Anuradha Chowdhary

Summary: The study revealed significant genetic and ecological diversities of Candida auris in healthcare settings, with 37.5% of patients with chronic respiratory diseases and 10% of fomite samples testing positive for the pathogen. Analysis showed multiple strains of C. auris infecting different body sites of patients and fomites.

JOURNAL OF FUNGI (2021)

Article Microbiology

Antifungal Activity of a Medical-Grade Honey Formulation against Candida auris

Theun de Groot, Tom Janssen, Dirk Faro, Niels A. J. Cremers, Anuradha Chowdhary, Jacques F. Meis

Summary: The study found that the medical-grade honey formulation has strong antifungal activity against Candida auris and other Candida species, but is slightly less effective than unprocessed local honey. Candida auris' susceptibility to the medical-grade honey formulation was not dependent on geographic origin or resistance profile, although multiresistant isolates tended to be more susceptible.

JOURNAL OF FUNGI (2021)

Article Infectious Diseases

Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology

Martin Hoenigl, Jon Salmanton-Garcia, Thomas J. Walsh, Marcio Nucci, Chin Fen Neoh, Jeffrey D. Jenks, Michaela Lackner, Rosanne Sprute, Abdullah M. S. Al-Hatmi, Matteo Bassetti, Fabianne Carlesse, Tomas Freiberger, Philipp Koehler, Thomas Lehrnbecher, Anil Kumar, Juergen Prattes, Malcolm Richardson, Sanjay Revankar, Monica A. Slavin, Jannik Stemler, Birgit Spiess, Saad J. Taj-Aldeen, Adilia Warris, Patrick C. Y. Woo, Jo-Anne H. Young, Kerstin Albus, Dorothee Arenz, Valentina Arsic-Arsenijevic, Jean-Philippe Bouchara, Terrence Rohan Chinniah, Anuradha Chowdhary, G. Sybren de Hoog, George Dimopoulos, Rafael F. Duarte, Petr Hamal, Jacques F. Meis, Sayoki Mfinanga, Flavio Queiroz-Telles, Thomas F. Patterson, Galia Rahav, Thomas R. Rogers, Coleman Rotstein, Retno Wahyuningsih, Danila Seidel, Oliver A. Cornely

Summary: With an increasing number of patients requiring intensive care or being immunosuppressed, infections caused by molds other than Aspergillus spp or Mucorales are on the rise. Antifungal prophylaxis has been effective, but breakthrough infections by other rare molds are also increasing. Regional differences should be considered in providing practical clinical decision guidance.

LANCET INFECTIOUS DISEASES (2021)

Article Immunology

Are We Ready for Nosocomial Candida auris Infections? Rapid Identification and Antifungal Resistance Detection Using MALDI-TOF Mass Spectrometry May Be the Answer

Elena De Carolis, Federica Marchionni, Marilisa La Rosa, Jacques F. Meis, Anuradha Chowdhary, Brunella Posteraro, Maurizio Sanguinetti

Summary: The present study aimed to implement MALDI-TOF mass spectrometry for species-level identification of C. auris isolates and develop a fast resistance detection assay. The MS-based assay showed potential for rapid diagnosis and appropriate treatment of patients with C. auris infection.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2021)

Article Microbiology

Two Candida auris Cases in Germany with No Recent Contact to Foreign Healthcare-Epidemiological and Microbiological Investigations

Joerg Steinmann, Thomas Schrauzer, Lisa Kirchhoff, Jacques F. Meis, Peter-Michael Rath

Summary: Candida auris poses a global fungal public health threat, with two cases reported in Germany showing multidrug resistance. Isolating patients and implementing contact precautions can effectively prevent nosocomial transmission of this emerging, multidrug-resistant pathogen.

JOURNAL OF FUNGI (2021)

Article Dermatology

In vitro activities of 8 antifungal drugs against 126 clinical and environmental Exophiala isolates

Mohammad Javad Najafzadeh, Somayeh Dolatabadi, Vania Aparecida Vicente, Gerrit Sybren de Hoog, Jacques F. Meis

Summary: This study investigated the in vitro activities of eight antifungal drugs against 126 clinical and environmental isolates of Exophiala species, revealing that posaconazole, itraconazole, and micafungin showed the best overall activity, while fluconazole was not considered an effective treatment choice. No significant difference was found in antifungal drug activities between different species of Exophiala, highlighting the importance of antifungal susceptibility data for managing this occasionally fatal infection.

MYCOSES (2021)

Article Dermatology

ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries

Shivaprakash M. Rudramurthy, Martin Hoenigl, Jacques F. Meis, Oliver A. Cornely, Valliappan Muthu, Jean Pierre Gangneux, John Perfect, Arunaloke Chakrabarti

Summary: Globally, the incidence of COVID-19-associated mucormycosis (CAM) is rising, with a significant surge in India. The need to address misconceptions in managing and treating this infection is crucial, with a focus on early suspicion, diagnosis confirmation, glycemic control, surgical debridement, and antifungal therapy. Limited availability of amphotericin B formulations during the epidemic has led to discussions on alternative antifungal therapies.

MYCOSES (2021)

Article Infectious Diseases

Molecular typing and antifungal susceptibility study of Aspergillus spp. in intensive care unit (ICU) patients in Indonesia

Anna Rozaliyani, Rudyanto Sedono, Ridhawati Sjam, Mulyati Tugiran, Robiatul Adawiyah, Findra Setianingrum, Anwar Jusuf, Saleha Sungkar, Ferry Hagen, Jacques F. Meis, Retno Wahyuningsih

Summary: The study investigated the incidence of invasive pulmonary aspergillosis (IPA) among ICU patients in Jakarta, Indonesia, identifying Aspergillus flavus as the main causative organism. All isolates showed susceptibility to amphotericin B, azoles, and micafungin.

JOURNAL OF INFECTION IN DEVELOPING COUNTRIES (2021)

Meeting Abstract Surgery

DISSEMINATED RHINOCLADIELLA MACKENZIEI INFECTION IN A KIDNEY TRANSPLANT RECIPIENT: CASE REPORT AND LITERATURE REVIEW

Osama Gheith, Torki Alotaibi, Khaled Alobiad, Prasad Nair, Sohair Zeineldein, Tarek Mahmoud, Medhat A. Halim, Hasaneen Aboatya, Mohamed Balaha, Khaled Atya, Ayman Maher Nagib, Abdullah Alhatmi, Amal Sadon, Jacques Meis, Mohamed Zahab

TRANSPLANT INTERNATIONAL (2021)

Article Immunology

COVID-19-Associated Pulmonary Aspergillosis, March-August 2020

Jon Salmanton-Garcia, Rosanne Sprute, Jannik Stemler, Michele Bartoletti, Damien Dupont, Maricela Valerio, Carolina Garcia-Vidal, Iker Falces-Romero, Marina Machado, Sofia de la Villa, Maria Schroeder, Irma Hoyo, Frank Hanses, Kennio Ferreira-Paim, Daniele Roberto Giacobbe, Jacques F. Meis, Jean-Pierre Gangneux, Azucena Rodriguez-Guardado, Spinello Antinori, Ertan Sal, Xhorxha Malaj, Danila Seidel, Oliver A. Cornely, Philipp Koehler

Summary: This study found that most patients with coronavirus disease-associated pulmonary aspergillosis (CAPA) are diagnosed shortly after admission, with the majority being treated in the ICU. Azole-resistant strains of Aspergillus fumigatus were common in patients, and voriconazole was the main treatment choice. The overall mortality rate was approximately 52.2%, with about one third of deaths attributed to CAPA.

EMERGING INFECTIOUS DISEASES (2021)

暂无数据